Efficacy of anti-PD-1 therapy. HCC was induced by HDI of MET/β-catenin.... | Download Scientific Diagram
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study - The Lancet Oncology
Immune responses to tumor-unrelated antigens might predict adverse effects in patients treated with anti-PD-1 immunotherapy | Cellular & Molecular Immunology
Learning from PD-1 Resistance: New Combination Strategies: Trends in Molecular Medicine
Anti–PD-1 Therapy in Melanoma - ScienceDirect
PDL1 e immunoterapici | L'immunologo risponde | alcase.eu
Agonistic anti-PD-1 antibodies turn on the immunosuppressive activity of PD- 1
Schematic representation of PD-1 and anti-PD-1/PD-L1 mechanisms of... | Download Scientific Diagram
PD-1
IJMS | Free Full-Text | PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action - Willsmore - 2021 - European Journal of Immunology - Wiley Online Library
Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles | Nature Communications
PD-1: Expanding Beyond Cancer Research | ProSci
Anti–PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases | Science Immunology
The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now - ScienceDirect
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Biomolecules | Free Full-Text | The Emerging Role of IL-9 in the Anticancer Effects of Anti-PD-1 Therapy
PD-1/L1 e anti-PD-1: test per il dosaggio della molecola e del farmaco – Listarfish.it – PRODOTTI PER RICERCA & DIAGNOSTICA
A Surprising Match: Cancer Immunotherapy and Mismatch Repair – NIH Director's Blog
Anti-hPD-1 antibodies | Pembrolizumab & Nivolumab biosimilar isotypes | InvivoGen
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | NEJM
Biomarkers of response to PD-1 pathway blockade | British Journal of Cancer
Frontiers | Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
Frontiers | PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
Current issues and perspectives in PD-1 blockade cancer immunotherapy | International Journal of Clinical Oncology
A Brief Introduction to PD-1 Antibodies and Immunotherapy | ProSci Incorporated
PD-1
